Eli Lilly (NYSE:LLY) announced yesterday that it would be ending its rheumatoid arthritis program for its drug tabalumab. In December, Lilly ended one of its three trials for this drug because it was showing no benefit, and it's now ended the other two trials for similar reasons. In the video, Brenton tells us about the drug's other potential application in the lupus space, and some other pipeline candidates it will be falling back on as it tries to gain share in the lucrative arthritis market.
Motley Fool Returns
Stock Advisor S&P 500
5 Years 57% 37%
17+ years 346% 95%
Stock Advisor launched in February of 2002. Returns as of 12/10/2019.Join Stock Advisor